Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd., a foreign private issuer, on January 4, 2018. The filing incorporates by reference a press release dated January 4, 2018, titled "Cellect Announces Breakthrough Clinical Results." The registrant files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a conduit for a press release regarding clinical developments rather than a financial statement.
Material Changes
The primary material change disclosed is the announcement of breakthrough clinical results, as detailed in the attached press release (Exhibit 99.1). No financial comparisons to prior periods are included in this specific filing text.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the attached press release into the company's Registration Statements on Form S-8 and Form F-3. The text does not explicitly detail the content of these statements, the specific risks, or the nature of the clinical results within the Form 6-K body itself.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for specific details on the "Breakthrough Clinical Results."
- Examine the incorporated "Forward Looking Statements" in the press release for potential risks and future projections.
- Verify the impact of these clinical results on the company's pipeline and potential regulatory milestones.
- Consult the most recent Form 20-F for the latest audited financial data, as this filing contains no financial figures.